Drugs / INO-1800
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02431312 | Jan 2015 → May 2018 | chronic hepatitis B virus infection | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-03-14 | Inovio Pharmaceuticals | Results Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection inovio.com ↗
These latest results from our Phase 1 trial indicate that treatment with INO-1800 is generating the type of immune response considered to be key in the treatment of chronic hepatitis B infection using an immunotherapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-03-14 | Inovio Pharmaceuticals | Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-1800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431312 ↗ |
| Modality | Vaccine | “DNA plasmids encoding Hepatitis B surface antigen” NCT02431312 ↗ |
| Route | Intramuscular | “Delivered IM Followed by EP” NCT02431312 ↗ |